Sutro Biopharma Valuation

Is S09 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of S09 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate S09's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate S09's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for S09?

Other financial metrics that can be useful for relative valuation.

S09 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does S09's PS Ratio compare to its peers?

The above table shows the PS ratio for S09 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.8x
HPHA Heidelberg Pharma
14.5x26.1%€138.4m
FYB Formycon
9.1x24.8%€705.5m
BIO3 Biotest
1.7x2.0%€1.4b
MDG1 Medigene
6.1x18.6%€37.0m
S09 Sutro Biopharma
1.8x27.4%€279.6m

Price-To-Sales vs Peers: S09 is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (7.8x).


Price to Earnings Ratio vs Industry

How does S09's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.1%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.1%
n/an/an/a
No more companies

Price-To-Sales vs Industry: S09 is good value based on its Price-To-Sales Ratio (1.8x) compared to the European Biotechs industry average (10.1x).


Price to Sales Ratio vs Fair Ratio

What is S09's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

S09 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.8x
Fair PS Ratio1.7x

Price-To-Sales vs Fair Ratio: S09 is expensive based on its Price-To-Sales Ratio (1.8x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst S09 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€3.14
€11.97
+281.2%
32.2%€18.57€7.43n/a9
Apr ’25€5.05
€12.77
+152.9%
39.4%€23.18€7.42n/a9
Mar ’25€4.46
€13.48
+202.2%
34.5%€22.98€7.35n/a9
Feb ’25€3.94
€13.48
+242.1%
34.5%€22.98€7.35n/a9
Jan ’25€3.88
€13.45
+246.7%
34.5%€22.93€7.34n/a9
Dec ’24€2.36
€14.52
+515.5%
37.2%€23.90€7.35n/a10
Nov ’24€2.56
€15.84
+518.7%
34.8%€24.38€7.50n/a9
Oct ’24€3.32
€16.25
+389.6%
32.0%€23.81€7.33n/a8
Sep ’24€4.32
€16.25
+276.2%
32.0%€23.81€7.33n/a8
Aug ’24€4.00
€17.19
+329.8%
28.1%€23.84€7.34n/a8
Jul ’24€4.20
€17.19
+309.4%
28.1%€23.84€7.34n/a8
Jun ’24€4.14
€17.48
+322.2%
28.1%€24.24€7.46n/a8
May ’24€4.00
€17.69
+342.1%
29.2%€23.73€7.30n/a8
Apr ’24€4.04
€18.21
+350.7%
28.3%€23.97€7.38€5.058
Mar ’24€5.20
€20.42
+292.7%
23.9%€30.46€13.84€4.468
Feb ’24€6.55
€20.42
+211.7%
23.9%€30.46€13.84€3.948
Jan ’24€7.25
€21.35
+194.5%
25.2%€32.96€14.98€3.888
Dec ’23€7.10
€21.35
+200.7%
25.2%€32.96€14.98€2.368
Nov ’23€7.30
€22.70
+211.0%
26.7%€33.11€15.05€2.568
Oct ’23€5.45
€22.70
+316.5%
26.7%€33.11€15.05€3.328
Sep ’23€5.55
€22.70
+309.0%
26.7%€33.11€15.05€4.328
Aug ’23€5.65
€26.46
+368.3%
25.6%€36.26€15.68€4.008
Jul ’23€4.92
€25.66
+421.5%
25.6%€35.16€15.20€4.208
Jun ’23€4.00
€25.34
+533.4%
27.4%€35.05€13.26€4.148
May ’23€5.75
€28.47
+395.1%
15.6%€34.53€18.67€4.008
Apr ’23€7.35
€27.69
+276.7%
15.6%€33.59€18.16€4.048

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.